Clinical Report: Solving the Problem of Insolubility: Part III

Overview

{'text': 'KinetiSol technology enables the dissolution of poorly soluble drug crystals into excipients without solvents or heat, facilitating new delivery methods, including parenteral delivery and dry powder inhalation, expanding the potential for previously undruggable molecules.'}

Background

{'text': 'The challenge of poor solubility in drug development affects nearly 40% of approved drugs and up to 90% of new chemical entities. This issue has significant implications for translating discovery compounds into effective therapies, necessitating innovative solutions like KinetiSol and others. The ability to enhance solubility can lead to improved patient outcomes and more efficient drug development processes.'}

Data Highlights

No numerical data provided in the article.

Key Findings

• KinetiSol allows for the dissolution of insoluble drug molecules into excipients without the use of solvents or heat.
• Recent research has enabled the formation of complexes suitable for parenteral delivery.
• Particle size reduction techniques have been developed for dry powder inhalation, enhancing drug delivery to the lungs.
• Awards and recognition for KinetiSol technology indicate growing industry acceptance and potential for commercial success.
• Political and social factors are pushing for more efficient drug development practices in response to rising expectations and challenges, impacting the industry landscape.

Clinical Implications

{'text': 'The advancements in KinetiSol technology may provide new avenues for delivering previously undruggable molecules, potentially improving treatment options for patients. Drug developers should consider these innovative solubility-enhancing methods to address the challenges of poor solubility in their formulations, particularly in the context of patient outcomes.'}

Conclusion

{'text': 'KinetiSol represents a significant advancement in drug delivery technology, with the potential to transform the landscape of drug development and improve therapeutic options for patients. Continued exploration and application of this technology may lead to enhanced patient outcomes.'}

References

1. the medicine maker, Source, 2026 -- Solving the Problem of Insolubility: Part II
2. the medicine maker, Source, 2026 -- Solving the Problem of Insolubility: Part I
3. Impact of Theobromine on the Dissolution of Uric Acid Kidney Stones, Source, 2022
4. the analytical scientist, Source, 2026 -- The Secret Life of a Solvent
5. New Strategies to Improve Drug Solubility and Its Impact on Bioavailability: A Patent Review (2015-2024), PubMed
6. Superior Serum Concentrations with Posaconazole Delayed-Release Tablets Compared to Suspension Formulation in Hematological Malignancies, PMC
7. Evaluation of a New Formulation That Improves the Bioavailability and Food Effect of Abiraterone: An Open-Label, Crossover, Randomized, Controlled, Phase I Clinical Trial, PubMed
8. New Strategies to Improve Drug Solubility and Its Impact on Bioavailability: A Patent Review (2015-2024) - PubMed
9. Superior Serum Concentrations with Posaconazole Delayed-Release Tablets Compared to Suspension Formulation in Hematological Malignancies - PMC
10. Evaluation of a New Formulation That Improves the Bioavailability and Food Effect of Abiraterone: An Open-Label, Crossover, Randomized, Controlled, Phase I Clinical Trial - PubMed